Fig. 2: Inhibitors are more sensitive to homozygous MTAP-deleted glioma cells, and their combination can produce a stronger synergistic lethal effect. | Cell Death Discovery

Fig. 2: Inhibitors are more sensitive to homozygous MTAP-deleted glioma cells, and their combination can produce a stronger synergistic lethal effect.

From: Combined inhibition by PRMT5 and MAT2A demonstrates a strong synthetic lethality in MTAP homozygous-deficient glioma models

Fig. 2

A–C CCK-8 assay to determine the viability of LN18, U87 and U251 cells after treatment with the PRMT5 inhibitor alone (10 nM), MAT2A inhibitor alone (10 nM), and with the inhibitor combination. D Mean IC50 values of the PRMT5 inhibitor for individual cell lines (n = 3). E LC–MS analysis of SAM levels in LN18, U87, and U251 cell lines. F Western blotting to determine the change trend in PRMT5, MAT2A, and SDMA in LN18, U87 and U251 cells (PRMT5i: 10 nM; MAT2Ai: 10 nM), and the statistical analysis bar chart (n = 3). G, H SynergyFinder 3.0 analysis for drug synergy with the PRMT5 inhibitor and MAT2A inhibitor in MTAP−/− glioma cells and MTAP+/+ glioma cells. Positive scores (red) indicate synergism, and negative scores (green) indicate antagonism (n = 3).

Back to article page